<DOC>
	<DOCNO>NCT00746954</DOCNO>
	<brief_summary>The purpose study determine whether buspirone compare acetazolamide placebo reduce number and/or severity breathe pause sleep occur patient Heart Failure .</brief_summary>
	<brief_title>Buspirone Potential Treatment Recurrent Central Apnea</brief_title>
	<detailed_description>The hypothesis buspirone safe , effective drug reduce occurrence recurrent central apnea irregular breathing find set heart failure . A secondary hypothesis effect similar acetazolamide . Study Design : A one-dose double-blind crossover study buspirone vs. placebo vs. acetazolamide perform determine active drug alters number and/or severity recurrent central apnea hypopnea ( AHI ) patient heart failure . AHI primary outcome variable . In initial phase study , recruit 18-20 patient obtain ~15 complete study , use assumption ~20 % drop-out , reach pre-set significance level 30 % reduction AHI drug group power 0.90 p=0.05 post-hoc testing . Power estimate calculate use mean SDs derive population report study acetazolamide Javaheri et al ( 2006 ) . A 30 % reduction AHI would meaningful . A 15 % dropout rate present study Javaheri et al ( 2006 ) , study three-way comparison , choose slightly high rate . The reason state article drop include : viral illness , GI upset ( placebo theophyllin ) , tired sleep study , desire terminate without cause . Statistical Analyses . Analysis variance repeat measure use Sidak 's correction use compare placebo , buspirone , acetazolamide study . For variable normally distribute , Dunn 's nonparametric test multiple comparison use . p &gt; 0.05 consider significant . Mean value SDs report . This single dose , one night study call Buspirone Potential Treatment Recurrent Sleep Apnea I . The randomization block design , analysis take account block design . We recruit 30 patient obtain ~27 complete study , use assumption ~25 % drop-out , reach pre-set significance level 50 % reduction AHI drug group power 0.90 p=0.05 post-hoc testing ( see Table C ) . Power estimate calculate use mean SDs derive population report study one week trial acetazolamide Javaheri , value similar drug trial theophyllin . Our reason 50 % reduction AHI would meaningful . Our drop-out rate one-night study estimate ~25 % . Exclusion criterion use selective serotonin reuptake inhibitor ( SSRIs ) antidepressant , necessary one drug buspirone , stringent completion study VA set . Of ~1000 patient chart screen , 8 eventually entered trial , power criterion meet . Records utilized probe hidden feature PSG use future drug trial .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea , Central</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>Ability provide inform consent , Ambulatory stable condition past 4 month , A diagnosis heart failure leave ventricular systolic dysfunction evidence ejection fraction &lt; 35 % , NYHA class II III clinical status , Diagnosis dilate cardiomyopathy ischemic cardiomyopathy . Unstable angina , unstable heart failure , acute pulmonary edema , congenital heart disease History unstable and/or advance hepatic disease History renal failure , CrCL &lt; 30 Current use SSRI , use within one month test Intrinsic pulmonary disease : ILD and/or COPD ( FEV1/FVC &lt; 65 % ) Kyphoscoliosis neuromuscular disease Suboptimally treat hypothyroidism Use narcotic benzodiazepine Use theophylline pseudoephedrine Use follow medication : MAO inhibitor diazepam haloperidol nefazodone trazodone erythromycin grapefruit juice itraconazole rifampin ketoconazole ritonavir , cimetidine Known allergy buspirone acetazolamide</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>buspirone</keyword>
	<keyword>acetazolamide</keyword>
</DOC>